Effect of Belimumab treatment on musculoskeletal and immunological manifestations in patients with systemic lupus erythematosus

Trial Profile

Effect of Belimumab treatment on musculoskeletal and immunological manifestations in patients with systemic lupus erythematosus

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Belimumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top